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Pain treatment after cesarean delivery is important for early mobilization and to enable the mother to care for the newborn child.
Ultrasound (US)-guided transversus abdominis plane 
(TAP) blocks are now widely used for postoperative analgesia 
after surgery with incision in the inferior part of the abdominal 
wall.1 However, standard TAP blocks provide inferior analge-
sia to neuraxial morphine and little benefit when added to a 
multimodal regimen that includes neuraxial morphine.2 The 
quadratus lumborum (QL) block, an US-guided abdominal 
wall block, was presented by Raphael Blanco as an abstract at 
the annual European Society of Regional Anaesthesia (ESRA) 
congress in 2007. A similar technique was later published as 
transversalis fascia plane block by Hebbard.3 In 2015, Blanco 
et al2 introduced a modified QL block technique with an injec-
tion site at the posterior border of the QL muscle. Theoretically, 
QL blocks might give better and longer lasting analgesia com-
pared to the US-guided anterior TAP block due to a spread 
KEY POINTS
• Question: Does quadratus lumborum block improve pain treatment after cesarean delivery?
• Findings: Opioid consumption in 24 hours was reduced, and the effective analgesic scores 
were significantly better in an active treatment group compared with the control group.
• Meaning: Quadratus lumborum block reduces the postoperative opioid consumption and pain 
intensity as a part of a multimodal analgesic regimen.
BACKGROUND: Landmark and ultrasound-guided transversus abdominis plane blocks have 
demonstrated an opioid-sparing effect postoperatively after cesarean delivery. The more poste-
rior quadratus lumborum (QL) might provide superior local anesthetic spread to the thoracolum-
bar fascia and paravertebral space. The aim of our study was to evaluate the efficacy of the QL 
block after cesarean delivery.
METHODS: A randomized, double-blind, controlled trial was performed. Forty parturients under-
going cesarean delivery received bilateral ultrasound-guided QL blocks with either 2 mg/mL 
ropivacaine or saline postoperatively. All patients received spinal anesthesia with bupivacaine 
and sufentanil and a postoperative analgesic regimen of paracetamol, ibuprofen, and ketobemi-
done administered by a patient-controlled analgesic pump. The ketobemidone consumption 
and time of each dose administered were recorded. The primary outcome was ketobemidone 
consumption during the first 24 hours postoperatively. Secondary and exploratory analyses 
compared repeated measures of pain scores, nausea, and fatigue, and total differences in time 
until patients were able to stand and able to walk 5 m, and the interaction between the effective 
analgesic score and time.
RESULTS: All 40 patients completed the trial, 20 in each group. The cumulative ketobemidone 
consumption in 24 hours was reduced in the active group compared with the control group 
(P = .04; ratio of means = 0.60; 95% confidence interval, 0.37–0.97). The effective analgesic 
scores were significantly better in the treatment group compared with the placebo group both at 
rest (P < .01) and during coughing (P < .01).
CONCLUSIONS: QL block with ropivacaine reduces the postoperative ketobemidone consump-
tion and pain intensity as a part of a multimodal analgesic regimen that excludes neuraxial 
morphine.  (Anesth Analg 2018;126:559–65)
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to the thoracic paravertebral space and sympathetic nerves in 
the thoracolumbar fascia.
The aim of our study was to evaluate the postcesarean 
analgesic effect of the US-guided lateral QL block.4 We 
tested the primary hypothesis that bilateral QL block with 
ropivacaine reduces cumulative ketobemidone consump-
tion during the first 24 hours after QL block, when com-
pared with bilateral placebo injection with saline. Secondary 
and exploratory analyses compared additional measures of 
analgesic quality and side effects between groups.
METHODS
Ethical approval for this study was provided by the 
Committee for Medical Research Ethics, Region South East, 
Oslo, Norway, on June 25, 2013 (Ethical Committee Number 
2013/1293-1; Document-id: 392062). The study was regis-
tered with a clinical trial registry (ClinicalTrials.gov identi-
fier: NCT02036749). Good Clinical Practice guidelines were 
followed. The trial was conducted and reported according to 
the Consolidating Standards of Reporting Trials (CONSORT) 
2010 statement.5 Study design was randomized, placebo-con-
trolled, and double blind, with parallel-group comparison.
The study was conducted at the Department of 
Anesthesiology, Division of Emergency and Critical Care, 
Oslo University Hospital, Rikshospitalet, between March 2014 
and April 2015. The study was funded by the Department of 
Anesthesiology. The Birth Clinic at Rikshospitalet is a tertiary 
care center, but the majority of the laboring women are healthy 
and reflect the general population in Southeast Norway. 
Forty healthy parturients scheduled for cesarean delivery 
via a Pfannenstiel incision gave written informed consent 
to participate in the study. Patients in American Society of 
Anesthesiologists classification II or stable American Society 
of Anesthesiologists III were included. Exclusion criteria 
were as follows: body mass index >32, chronic pain, neuropa-
thy, age <18 or >45 years old, allergy to local anesthetic (LA), 
inadequate Norwegian language skills, or inability to operate 
a patient-controlled analgesia (PCA) pump.
All patients had spinal anesthesia with 10 mg of isobaric 
bupivacaine with 4 μg of sufentanil. Postoperatively both 
groups received a basic analgesic regimen of oral paracetamol 
1 g and ibuprofen 400 mg, dosed together 4 times daily. A 
CADD-Legacy (Smith Medical MD, Inc, St Paul, MN) PCA 
pump with ketobemidone 1 mg/mL was programmed with 
a 1-mg demand dose, a lockout of 8 minutes, and a maxi-
mum dose of 7 mg/h. Patients were instructed to administer 
PCA boluses to achieve acceptable pain control not exceed-
ing a pain level at rest of 3 on a numeric rating scale (NRS). 
Ketobemidone is regarded as equianalgesic to morphine.6,7
The QL blocks were performed in the postoperative care 
unit within the first hour after cesarean delivery, before the 
patients experienced any postoperative pain or pain dur-
ing the QL block procedure. Routine monitoring included 
electrocardiogram, pulse oximetry, and noninvasive arterial 
blood pressure. Three consultant anesthesiologists expe-
rienced in US-guided regional anesthesia (A.K., K.U., and 
A.R.S.) performed the blocks.
QL Block Performance
A modified technique combining the techniques described 
by Blanco et al2 and Hebbard3 were used for the blocks. A 
SonoSite Edge ultrasound unit (SonoSite, Bothell, WA) with 
a HFL50, 6–15-MHz linear transducer was used. The patients 
were in the supine position. The side to be blocked was 
slightly elevated by pillows underneath the hip and shoul-
der. The transducer was placed in the transverse plane on the 
flank of the patient cranially to the iliac crest, at the level of the 
umbilicus (Supplemental Digital Content 1, Figure 1, http://
links.lww.com/AA/C136). The muscle layers of the abdomi-
nal wall were identified. The transducer was then moved 
posteriorly to visualize the aponeurosis of the transversus 
abdominis muscle. The pararenal fat and the QL muscle 
were imaged medial to the aponeurosis (Figure 1). A Vygon 
Echoplex 21G 100-mm needle (Vygon SA, Ecouen, France) 
was advanced in-plane under US guidance in anteroposterior 
direction through the muscle layers of the abdominal wall. 
The needle tip was advanced to the transversus aponeurosis 
and positioned superficial to the pararenal fat and lateral to 
the border of the QL muscle. Two milliliters of the study medi-
cine (ropivacaine 2 mg/mL or saline 9 mg/mL) were injected 
to verify the needle position. If necessary, the needle was repo-
sitioned. On each side, volume of 0.4 mL/kg study solution 
with a maximum of 30 mL was then injected under repeated 
aspiration for every fifth milliliter injected. Hence, for the 
bilateral procedures in the active group, a total amount of 1.6 
mg/kg ropivacaine with a maximum of 120 mg was used.
The exact time of each ketobemidone bolus was recorded 
in the internal memory of the PCA pumps and extracted to a 
computer with CADD-Sentry Medication Delivery Manager 
software package (Smith Medical MD, Inc, St Paul, MN) The 
patients registered pain severity at rest and when coughing 2, 
4, 6, 12, 24, and 48 hours after the QL block using NRS scales 
(0 = no pain, 10 = worst pain imaginable). Nausea and fatigue 
were also registered by the patients using NRS scales at the 
same time intervals. In addition, the patients registered the 
first time standing on their feet and when they walked 5 m.
Outcome Variables
The primary outcome was ketobemidone consumption dur-
ing the first 24 hours after QL block. Secondary outcomes 
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Figure 1. QL block technique: an injection needle is advanced in-plane 
under US guidance in anteroposterior direction through the muscle 
layers of the abdominal wall to the transversus aponeurosis (white 
arrows). The needle tip is positioned superficial to the pararenal fat 
and lateral to the border of the QL muscle. EO indicates external 
oblique muscle; IO, internal oblique muscle; trans. abd., transversus 
abdominis muscle; LA, local anesthetic; QL, quadratus lumborum.
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were ketobemidone consumption during 12, 36, and 48 
hours, pain intensity (PI) (NRS) scores, the integrated scores 
for pain, nausea, and fatigue, and time to mobilization. All 
other comparisons were exploratory.
Randomization and Blinding
Patients were randomly assigned to either QL block with 
ropivacaine 2 mg/mL (n = 20) or saline 9 mg/mL (pla-
cebo) (n = 20). A person not involved in the data collection 
or in patient care randomly assigned the patients in blocks 
of 8 or 6, into 2 groups of equal size using a list of random 
numbers,8 according to the Moses–Oakford algorithm.9 
The block size (8 or 6) was also randomized using a list 
of random numbers. Block size and randomization codes 
were not revealed to the investigators until all measure-
ments and calculations had been entered into the data-
base for all patients. Each patient, the investigators, and 
all medical caregivers were blinded to group allocation.
One hour before the QL block procedure of an enrolled 
patient, a nurse, not otherwise participating in the study, 
opened a sealed opaque envelope containing group alloca-
tion. The nurse then filled 4 syringes (2 × 20 mL and 2 × 10 
mL) labeled “study medicine” with the allocated solution, 
either ropivacaine 2 mg/mL or saline.
All data were entered in the database before entering the 
randomization codes. The principles for intention-to-treat 
analysis were followed.
Statistics
All the statistical analyses were performed using Statistical 
Package for the Social Sciences (SPSS) version 22 (IBM Corp, 
Armonk, NY).
Histograms, box plots, Q-Q plots, and the Kolmogorov–
Smirnov test were used to assess whether the variables and 
the residuals were normally distributed.
The primary hypothesis was that the main cumula-
tive ketobemidone consumption after 24 hours (primary 
outcome variable) was less in the active treatment group 
compared with the control group. Data for this primary out-
come variable ketobemidone consumption was estimated 
as log-normal distributed. Therefore t tests for independent 
samples were used with log-transformed data. The data are 
given as ratio of means and confidence intervals (CIs).
PI (NRS) and ketobemidone consumption were inte-
grated in an effective analgesic score (EAS), both secondary 
outcomes of the study. EAS was calculated using the for-
mula: (NRS + 1) × (1 – K/10), where K indicates doses (mg) 
of ketobemidone consumption 2 hours before registration 
time point of NRS.10 The original formula has been modi-
fied as NRS + 1 replaces PI to avoid a zero product in case of 
NRS = 0. The modified EAS score represents an integration 
of both pain and analgesic consumption at every time point, 
even if pain score is zero.
Oxycodone was converted into ketobemidone equiva-
lents and added to cumulative ketobemidone consumption 
(5 mg of short-acting oxycodone was considered equivalent 
to 3.3 mg of intravenous ketobemidone distributed over 4 
consecutive hours; 10 mg of long-acting oxycodone was 
considered equivalent to 6.7 mg of intravenous ketobemi-
done distributed over 12 consecutive hours).
Cumulative consumption of ketobemidone at 24 hours 
was the primary end point of our study. Given statistically 
significant group difference in the primary end point (level 
of significance P < .05), analyses of secondary end points 
were performed. Differences in EAS at rest (EAS rest) and 
during coughing (EAS evoked) at 2, 4, 6, 12, 24, and 48 
hours were analyzed in the 2 treatment groups. We used 
the linear mixed model in SPSS to test if the development 
of EAS over time differed between the 2 treatment groups; 
that is, an interaction effect (type III test of fixed effects, F 
test). Baseline (time point 2 hours after study drug injec-
tion) was used as reference point. Level of significance in 
the secondary outcome analyses was P < .01 to account 
for multiple comparisons. The residuals were checked for 
normality, and the assumption was found satisfied.
For nonparametrical data including NRS scores for fatigue 
and nausea (secondary outcomes), 2-sample Wilcoxon 
rank sum tests were used.
Sample Size
Sample size calculation was performed using SPSS 
SamplePower (IBM Corp, Armonk, NY). Our primary 
hypothesis was that opioid consumption after 24 hours was 
less in the active treatment group. We considered a 40% 
reduction in cumulative opioid consumption as clinically 
relevant. Based on previous studies on opioid consumption, 
a standard deviation (SD) of 40% was estimated. A sample 
size of 17 patients in each group would give 80% power to 
detect a 40% reduction in opioid consumption, using t tests 
with α = .05. Estimating a mean cumulative ketobemidone 
consumption of 50 mg (SD, 20 mg), a reduction of 20 mg 
could be detected. Forty patients were included in the study 
to allow missing data or dropouts.
RESULTS
Sixty-one patients were considered eligible; of these 40 
patients were randomly assigned and included in analysis 
(Figure 2). Baseline characteristics are shown in Table 1. The 
mean age showed a statistically significant difference of 2 
years. Other baseline characteristics did not show signifi-
cant differences. Three patients (1 in the active group and 2 
in the control group) received oral oxycodone at 30, 32, and 
33 hours, respectively, after the QL block.
Primary Outcome
Patients receiving the active QL block had lower cumula-
tive ketobemidone consumption at 24 hours, compared 
with the control group (P = .04; ratio of means = 0.60; 95% 
CI, 0.37–0.97). Figure 3 shows the cumulative ketobemidone 
consumption per hour in both study groups.
Secondary Outcomes
At 12 hours, the cumulative ketobemidone consumption 
was significantly lower in the active group compared with 
the control group (P < .01; ratio of means = 0.52; 95% CI, 
0.35–0.79). No statistically significant differences were 
found at 36 hours (P = .13; ratio of means = 0.71; 95% CI, 
0.45–1.12) or at 48 hours (P = .20; ratio of means = 0.74; 95% 
CI, 0.47–1.18).
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The analyses of the interactions between time 
(0–48 hours) and treatment showed statistically significant 
group differences in PI at rest (P < .01) and when the patients 
were coughing (P < .01) (Figure  4A, B). The interactions 
between time (0–48 hours) and treatment analyses showed 
statistically significant differences in EAS at rest (P < .01) 
and when the patients were coughing (P < .01) (Figure 4C, 
D). The PI at rest and during coughing and the estimated 
analgesic score at rest and during coughing are presented in 
Table 2 (mean difference and 95% CI).
The patients’ experience of fatigue was similar in both 
groups. Median NRS scores for nausea were 0 at all mea-
surement time points in both groups, and no significant 
difference could be found (Supplemental Digital Content 2, 
Table 1, http://links.lww.com/AA/C137).
Patients in the active group were able to stand 14.5 hours 
(SD, 1.6) after QL block, while patients in the control group 
were able to stand after 13.5 hours (SD, 1.5) (P = .66; difference 
Table 1. Baseline Characteristics
Variable
Active  
Group
Control  
Group P
Age (y) 34 ± 4 36 ± 4 .03
Weight (kg) 74 ± 7 79 ± 9 n.s.
Height (cm) 169 ± 5 168 ± 5 n.s.
ASA (1/2/3) 0/16/4 0/14/6 n.s.
BMI (kg/m2) 26 ± 3 28 ± 3 n.s.
Total dose of study medicine (mg) 114 ± 8 114 ± 14 n.s.
Data are presented as mean ± SD and counts.
Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass 
index; n.s., not significant.
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Figure 3. Cumulative ketobemidone consumption (mg) per hour for 
the patients treated with QL block (thick green line) with 95% per-
centiles (thin green lines) and for the patients in the control group 
(dashed blue thick line) with 95% percentiles (dashed blue thin 
lines). QL indicates quadratus lumborum.
Assessed for eligibility (n = 61)
Excluded  (n = 21)
♦   Not meeting inclusion criteria (n = 6)
♦   Declined to participate (n = 15)
  
Analysed  (n = 20)
♦ Excluded from analysis (n = 0) 
Lost to follow-up (n = 0)
Discontinued intervention (n = 0)
 
Allocated to intervention (n = 20)
♦ Received allocated intervention (n = 20) 
♦ Did not received allocated intervention (n =  0) 
 
Lost to follow-up (n = 0)
Discontinued intervention (n = 0)
Allocated to intervention (n = 20)
♦ Received allocated intervention (n = 20) 
♦ Did not received allocated intervention (n =  0) 
 
Analysed  (n = 20)
♦ Excluded from analysis (n = 0)
 
Allocation 
Analysis 
Follow-Up 
Randomized (n = 40)
Enrollment 
Figure 2. Study flowchart.
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of mean = −1.00; 95% CI, −5.48 to 3.49). In the active group, 
patients were walking at least 5 m after 19.1 hours (SD, 
1.8), while patients in the control group were walking 5 m 
or more after 17.2 hours (SD, 1.8) (P = .44; difference of 
mean = −1.97; 95% CI, −7.13 to 3.18).
There were no complications or adverse events.
DISCUSSION
Our randomized controlled trial demonstrated a 41% opi-
oid-sparing effect of the QL block during the first 24 hours 
postoperatively after cesarean delivery, when administered 
with multimodal analgesia in the absence of neuraxial 
morphine.
In 2008, McDonnell et al11 described the TAP block to 
anesthetize the lower anterior abdominal wall after cesar-
ean delivery. Patients receiving active TAP blocks had a 
morphine-sparing effect of 70% compared to the control 
group. The LA doses used by McDonnell et al11 were 150 mg 
of ropivacaine, compared to the maximum dose of 60 mg 
each side in our study. A higher dose of LA may increase the 
efficacy and/or the duration of the QL block and may also 
produce high serum concentrations of local anesthetic, lead-
ing to both a systemic analgesic effect12 and risk for systemic 
side effects and toxicity.13
In systematic review published by Abdallah et al1 in 
2012, only 3 of 6 randomized controlled studies showed 
a reduction of morphine consumption when therapeutic 
TAP block is performed after cesarean delivery. In 2016, 
Champaneria et al14 published a meta-analysis of 20 studies 
that confirmed TAP blocks can be effective for acute pain 
relive after cesarean delivery. However, TAP blocks did not 
confer additional analgesia when intrathecal hydrophilic 
opioids were used.
Blanco et al2 published the first study investigating the 
analgesic effect of QL block after cesarean delivery, in which 
0.2 mL/kg 0.125% bupivacaine was injected on the pos-
terolateral border of the QL muscle. A significant reduction 
in the morphine consumption and visual analogue scores 
scores was found during 48 hours after QL block admin-
istration.2 In a second trial, this group compared QL block 
with TAP block and found a significantly superior effect of 
the QL block lasting from 6 to 48 hours.15
Two theories explain why injection at the posterolateral 
border of the QL muscle may achieve superior pain relief 
when compared with standard anterior TAP blocks. First, 
the QL block may facilitate spread of LA into the paraverte-
bral space, theoretically prolonging the block and achieving 
visceral pain relief. Alternatively, Blanco et al2 posit that LA 
spread to a network of sympathetic nerves in the thoraco-
lumbar fascia can explain the long-lasting analgesic effect.15
During pilot studies, our group of anesthetists was unable 
to consistently establish sensory blockades when injecting 
LA at the posterior border of the QL muscle. The QL block 
technique that was used in our study (Figure 1) is similar to 
the methods originally described by Raphael Blanco as an 
abstract at the annual ESRA congress in 2007 and the “fascia 
transversalis sheath block” published by Hebbard.3 When 
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Figure 4. Pain intensity (NRS, 0–10) 
at rest (A) and during coughing (B) pre-
sented as mean (± 2 SEM), and EAS 
(= [NRS + 1] × [1 + K/10], where K = mg 
of ketobemidone the 2 h before registra-
tion) at rest (C) and during coughing (D) 
presented as mean (± 2 SEM). EAS indi-
cates estimated analgesic score; NRS, 
numeric rating scale.
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injecting between the transversus aponeurosis and the para-
renal fat lateral to the QL muscle, a slow reabsorption of LA 
may lead to prolonged analgesic effect of a single injection.
In contrast to Hebbard,3 we did not try to identify the 
very thin fascia transversalis medially to the transversus 
aponeurosis by US. We therefore do not know if the LA was 
injected medial or lateral to the fascia transversalis. When 
dissecting the abdominal wall in cadavers, the anterior 
abdominal branches of L1 could be found within the fas-
cia transversalis on the medial side of the transversus apo-
neurosis (unpublished data). When the aponeurosis turns 
into the transversus abdominis muscle, the nerves regularly 
enter the TAP plane (unpublished results). We expect that 
LA injected medial to the aponeurosis can reach the nerves 
from either side of the thin fascia transversalis layer.
We did not find a clinically relevant opioid-sparing effect 
of the QL block in the 24–48-hour period. Catheter-based 
QL blocks might prolong the analgesic effect.
Compared with the control group, the patients with QL 
block had a nonsignificant trend toward a delay in ambula-
tion. Theoretically, a spread to the lumbar plexus can cause 
weakness of the psoas, iliacus, and quadriceps muscles as 
described in a case report by Wikner.16 However, no obvi-
ous effects of a lumbar plexus block have been observed in 
our patients.
Limitations
US-guided needle placement is an operator-dependent 
technique. In our study, we wanted to ensure correct place-
ments by having a second investigator confirm the correct 
needle placement as imaged by US. We did not assess block 
success by sensory testing in our study. The lack of a sen-
sory test was chosen to preserve blinding of group alloca-
tion. The optimal dose of LA for QL blocks is not known, 
and our study cannot provide information on the adequate 
dose. A higher dose of ropivacaine may have improved 
and prolonged the analgesic effect. We excluded patients 
with body mass index >32 to ensure homogeneous patient 
groups. We therefore do not know if QL blocks are as effec-
tive in obese patients.
Postoperative ibuprofen and paracetamol were admin-
istered in addition to PCA ketobemidone. Despite this mul-
timodal analgesic regime, which may have obscured some 
of the effects of the QL blockade, the study was adequately 
powered to identify an opioid-sparing effect in the first 24 
hours. Patients were instructed to use their PCA pumps 
to achieve a NRS at 3 or less. This instruction may limit 
the value of examining the difference in PI between the 
groups. However, patient-reported PI was lower in the first 
12 hours in the active group, and the analyses of EAS—
integrating PI and PCA opioid consumption—supported 
the observation of clinically and statistically significant 
group differences.
The assessment of PI and analgesic consumption in 
clinical pain trials is challenging. The introduction of an 
estimated analgesic score enables the researchers to pres-
ent a combined outcome measure of improved validity. 
Presenting PI, analgesic consumption, and the integration 
of both is informative, but the analyses of potential differ-
ences in treatment effects are still challenging and represent 
a limiting factor.
The study included pregnant women scheduled for 
planned cesarean delivery under standard anesthesia, and 
the postcesarean pain treatment was only slightly modi-
fied compared to the standard practice in the department. 
The sample is representative for the population at our birth 
clinic, and a majority of the screened patients were eligible 
for participation. However, generalizability is limited to 
those institutions and clinical contexts in which neuraxial 
morphine is not available.
CONCLUSIONS
Ropivacaine US-guided QL block reduced postoperative 
ketobemidone consumption and pain after cesarean delivery. 
The patients received small doses of ropivacaine, and further 
trials must be conducted to evaluate the ideal dose, volume, 
and injection site. Future studies should compare the analge-
sic efficacy with a multimodal regimen that includes neur-
axial morphine; analgesic outcomes of QL block and more 
traditional US-guided TAP block should be directly com-
pared. E
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Table 2.  Pain Intensity and Estimated Analgesic 
Scores 
Time (h)
Mean Difference   
(Control – Ropivacaine) 99% CI
Pain intensity (NRS) at rest (h)  
 2 0.65 −0.30 to 1.61
 4 1.05 −0.81 to 2.91
 6 1.05 −0.66 to 2.76
 12 −0.55 −2.67 to 1.58
 24 −0.80 −2.90 to 1.30
 48 0.05 −1.22 to 1.32
Pain intensity (NRS) during coughing  
(evoked pain) (h) 
 
 2 1.55 −0.28 to 3.38
 4 1.60 −0.34 to 3.54
 6 1.20 −0.66 to 3.06
 12 −0.50 −2.55 to 1.55
 24 −1.10 −2.96 to 0.76
 48 −0.10 −1.68 to 1.48
EAS at rest (h)   
 2 0.85 −0.27 to 1.97
 4 1.26 −0.70 to 3.22
 6 1.23 −0.54 to 2.99
 12 −0.38 −2.63 to 1.88
 24 −0.74 −2.87 to 1.40
 48 0.85 −1.19 to 1.36
EAS during coughing (evoked) (h)  
 2 1.75 −0.23 to 3.72
 4 1.81 −0.22 to 3.84
 6 1.38 −0.52 to 3.27
 12 −0.33 −2.45 to 1.80
 24 −1.04 −2.92 to 0.85
 48 −0.65 −1.64 to 1.51
The table presents the results of the linear mixed-model analyses of pain 
intensity measured as NRS 0–10 and the integrated pain intensity + 
analgesic consumption variable EAS. Pairwise comparisons are presented as 
group differences, 99% CI.
Abbreviations: CI, confidence interval; EAS, estimated analgesic score; NRS, 
numeric rating scale.
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